Three young Swiss medtech companies have announced progress, according to a roundup of press releases published on October 15, 2026 by Startupticker.ch. OxyPrem has obtained CE marking for its NOAH tissue oximeter, Positrigo’s NeuroLF system has become the first brain-dedicated PET device to receive EARL accreditation, and MindMaze Therapeutics has presented real-world results from a programme run with Vibra Healthcare. Three milestones of a different nature: a regulatory approval, an image-quality accreditation and usage data. None of them says the same thing, and none of them says everything.

OxyPrem: NOAH obtains CE marking

OxyPrem’s NOAH Tissue Oximeter System has received CE marking under the European Medical Device Regulation (MDR 2017/745). The press release states that the company is now preparing its commercial launch in Europe and that the system is available in markets that recognise CE marking. The device relies on near-infrared spectroscopy (NIRS) and measures tissue oxygenation non-invasively and continuously, including in the brains of premature babies.

The method is not new: NIRS has been in use for more than 25 years and has given rise to more than 14,000 research publications. According to the source, its difficulties lie in sensor accuracy and ease of use. This is where OxyPrem is positioning itself. Its NOAH Sensor Small analyses tissue with more than 10 wavelengths and shows an accuracy (ARMS) of 2.5% in the StO₂ ranges of 35–55% and 50–85% in newborns. A dynamic self-calibration algorithm is intended to reduce preparation time. The reusable sensor has a biocompatible silicone shell and is attached without adhesive, with a simple bandage or under a CPAP cap.

What the milestone validates: the device’s compliance with the European regulatory framework, which opens up market access. What it does not prove: the 2.5% accuracy is a figure reported by the company, and the source presents no data on the device’s effect on care in neonatal intensive care.

Positrigo: EARL accreditation for NeuroLF

Positrigo’s NeuroLF is an ultra-compact positron emission tomography (PET) system designed solely for brain imaging. Its small footprint is meant to bring PET closer to neurology practices and imaging centres, without the infrastructure required by conventional whole-body PET/CT systems.

The device installed at LMU Klinikum in Munich has received accreditation from the EANM Research Ltd. (EARL) programme. This initiative of the European Association of Nuclear Medicine (EANM) aims to harmonise and standardise PET imaging across centres in Europe, to ensure consistent image quality and comparable quantitative measurements. This is an important criterion for multicentre clinical studies and long-term follow-ups. The process was led by the nuclear medicine department of LMU Klinikum, which uses NeuroLF clinically and in research on neurodegenerative diseases.

What the milestone validates: the images produced by this installation meet European comparability standards, which allows the device to be included in multicentre studies. What it does not prove: the source provides no data on NeuroLF’s diagnostic performance.

MindMaze: home rehabilitation data

MindMaze Therapeutics has presented new data from a programme run across several sites with Vibra Healthcare. It is a retrospective quality-improvement programme, without a control group. It covered 177 rehabilitation episodes in 172 adults with various neurological conditions, mainly strokes, at four Vibra Healthcare outpatient sites. Participants followed an eight-week home training programme with MindMotion GO, with an optional four-week extension and periodic supervision by a therapist.

According to the company, home use of MindMotion tripled, in median terms, the total dose of motor training compared with usual outpatient therapy alone. 84% of active training was carried out independently, without direct supervision. Participants also showed statistically significant improvements in functional independence, balance, mobility and cognition, and high satisfaction.

What the milestone validates: the feasibility of more intensive home training, with a large share of autonomy, under real-world care conditions. What it does not prove: without a control group and on a retrospective basis, the programme does not make it possible to attribute the observed progress to the tool rather than to spontaneous recovery or usual care. MindMaze sees it as support for its intensive home rehabilitation strategy, ahead of the launch of MindMotion Lite, a tablet version announced for late 2026. This product is not yet on the market.

Sources